 "Mankind Pharma aims at Rs 5,000-cr top line")
The company says it would achieve the targeted top line by focusing on chronic segments, neutraceuticals, cosmetology and newer markets as the future growth drivers.
"We are identifying overseas markets, have entered the cosmetics segment and are strengthening ourselves in the cardiovascular and anti-diabetic drug categories. The API plant that we are coming up with would focus on enabling the company to make affordable drugs," R C Juneja, chairman and founder of Mankind Pharma said in a statement.
The company was also planning to enter marketing tie-ups with multinational pharma majors to launch their patented products in the Indian market, he said. The company started exporting its products to the emerging markets apart from looking at enhancing its presence in the US in the next 18 months, according to the statement.
Mankind Pharma has over 1,000 brands spanning medicines categories such as antibiotics, antifungal, gastro intestinal, cardio vascular dermatology among others, it said.